Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197231 | 0.75 | BLM (0.34) | BLMCA1TSHR | |
| SCHEMBL28478835 | 0.75 | BLM (0.30) | BLM | |
| SCHEMBL1784505 | 0.75 | BLM (0.44) | BLMCA1GABRR1CYP1A2ALDH1A1 | |
| Hydrogen Peroxide SCHEMBL9341267 | 0.73 | TSHR (0.46) | BLMLMNACA1TSHRCYP1A2 | |
| SCHEMBL10696984 | 0.73 | — | — | |
| SCHEMBL99840 | 0.73 | — | — | |
| SCHEMBL21931322 | 0.73 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL3336438 | 0.73 | ACE2 (0.35) | BLMTSHR | |
| SCHEMBL83493 | 0.73 | — | — | |
| SCHEMBL16469013 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558986-A1 | SUBSTITUTED 1,2,4-THIADIAZOLYL PYRROLONES AND 1,2,4-THIADIAZOLYL HYDANTOINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-4196267-A1 | NOVEL RUTHENIUM COMPLEXES, METHODS OF THEIR PREPARATION AND APPLICATION THEREOF IN OLEFIN CROSS METATHESIS | Apeiron Synthesis S.A. (PL) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022038121-A1 | NOVEL RUTHENIUM COMPLEXES, METHODS OF THEIR PREPARATION AND APPLICATION THEREOF IN OLEFIN CROSS METATHESIS | APEIRON SYNTHESIS S.A. (PL) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021130622-A2 | RUTHENIUM COMPLEX AND METHOD OF CONDUCTING OLEFIN METATHESIS REACTIONS WITH FORMATION OF AN INTERNAL BOND USING THE RUTHENIUM COMPLEX AS A CATALYST | APEIRON SYNTHESIS S.A. (PL) | 2021-07-01 | — | — | WO | disclosed |
| EP-2718016-B1 | NEW COMPLEXES OF RUTHENIUM, METHOD FOR THEIR PREPARATION, AND THEIR APPLICATION IN OLEFIN METATHESIS REACTIONS | UMICORE AG & CO KG (DE) | 2019-08-14 | — | — | EP | disclosed |
| EP-3262056-A2 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | Sarepta Therapeutics, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| WO-2017184529-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-1505125-A1 | Cyanine compound, optical recording material, and optical recording medium | Asahi Denka Co., Ltd. (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-20040197705-A1 | Cyanide compound, optical filter, and optical recording material | ASAHI DENKA CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1464678-A1 | Cyanine compound, optical filter, and optical recording material | Asahi Denka Co., Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-1053241-A1 | NOVEL DIMERIZING AGENTS, THEIR PRODUCTION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-1030853-A1 | NOVEL SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM | ARIAD PHARMACEUTICALS, INC. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999041258-A1 | NOVEL DIMERIZING AGENTS, THEIR PRODUCTION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999024442-A1 | NOVEL SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM | ARIAD PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5706829-A | BENZODIAZEPINE DERIVATIVE | CREIGHTON UNIVERSITY (US) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | BLM 1161/4885LMNA 2961/4885CA1 1239/4885 |
| US-20040197705-A1 | Cyanide compound, optical filter, and optical recording material | HCN4, HCN2, HCN1 | BLM 3104/4885LMNA 1862/4885CA1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.